Karl D. Hargrave

Statistics

Publications

Citations

2.4K

H-Index

Active since

1976

Affiliations

Boehringer Ingelheim (United States)(Current)

Boehringer Ingelheim (Brazil)

Boehringer Ingelheim (Japan)

University of Massachusetts Chan Medical School

Boehringer Ingelheim (France)

Karl D. Hargrave is an author at Boehringer Ingelheim (United States) specializing in medicinal chemistry, enzyme inhibition, and antiviral pharmacology.

Publications per year

1976–2002

Publications

Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor

Vincent J. Merluzzi, Karl D. Hargrave, Mark E. Labadia et al. · Science · 1990 · 746 citations

Life Sciences, Medicinal Chemistry, Molecular Biology +17

N-(4-Substituted-thiazolyl)oxamic acid derivatives, new series of potent, orally active antiallergy agents

Karl D. Hargrave, Friedrich K. Hess, James T. Oliver · Journal of Medicinal Chemistry · 1983 · 321 citations

Pharmacy, Medicinal Chemistry, Pharmacology +9

Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease

James J. Crute, Christine A. Grygon, Karl D. Hargrave et al. · Nature Medicine · 2002 · 231 citations

Life Sciences, Microbiology, Molecular Biology +13

Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones

Karl D. Hargrave, John Proudfoot, Karl Grozinger et al. · Journal of Medicinal Chemistry · 1991 · 208 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones

Janice M. Klunder, Karl D. Hargrave, M. L. WEST et al. · Journal of Medicinal Chemistry · 1992 · 144 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

1–5 of 19